BREAKWATER safety lead-in (SLI): Encorafenib (E) plus cetuximab (C) plus chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC)

by biblioteca on 22 de gener de 2024 with No hi ha comentaris

Kopetz, S., Yoshino, T., Kim, T. W., Yaeger, R., Desai, J., Wasan, H. S., . . . Tabernero, J. (2023). BREAKWATER safety lead-in (SLI): Encorafenib (E) plus cetuximab (C) plus chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 41, 119-119. https://doi.org/10.1200/JCO.2023.41.4_suppl.119